Atossa Therapeutics (ATOS) Receivables (2011 - 2017)

Atossa Therapeutics (ATOS) posted quarterly Receivables of $4040.0 for Q3 2017, down 99.62% quarter-over-quarter from $1.1 million in Q3 2015.

Atossa Therapeutics (ATOS) Receivables (2011 - 2017) Analysis & Trends

Atossa Therapeutics (ATOS) has reported Receivables for 6 consecutive years, with $4040.0 the latest figure, recorded in Q3 2017.

In Q3 2017, Receivables changed N/A year-over-year to $4040.0; the TTM figure through Sep 2017 stood at $4040.0 (changed N/A YoY), while the FY2014 annual figure was $297958.0, up 114.25% from the prior year.
Receivables retreated to $4040.0 in Q3 2017 per ATOS's latest filing, from $1.1 million in the prior quarter.
Across five years, Receivables topped out at $2.0 million in Q2 2015 and bottomed at $4040.0 in Q3 2017.
Historically, Receivables has averaged $503026.2 across 4 years, with a median of $278648.5 in 2013.
Annual changes were most pronounced in 2014 — Receivables tumbled 90.75% — and 2015, when it jumped 4078.49%.
Atossa Therapeutics' Receivables stood at $139072.0 in 2013, then surged by 114.25% to $297958.0 in 2014, then soared by 254.1% to $1.1 million in 2015, then plunged by 99.62% to $4040.0 in 2017.
Business Quant data shows ATOS's Receivables at $4040.0 in Q3 2017, $1.1 million in Q3 2015, and $2.0 million in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn	1.93 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	-
10	Atossa Therapeutics	23.07 Mn	23.07 Mn	-	-

Download Data